MIT team reports an automated route to more controlled LNP production
MIT News reports a two-stage process that measures lipid nanoparticle size during production and uses the resulting data to guide processing conditions for RNA-therapy development. The team is pursuing commercialisation through BIZON Labs; no clinical testing is reported.
- Published by
- MIT News
- Evidence type
- Laboratory
MIT researchers have reported an automated process for producing lipid nanoparticles with tighter control over size and shape. The approach combines dynamic light scattering during processing with a machine-learning model that predicts settings for a desired particle profile.
The work is presented as a development and manufacturing tool for RNA and DNA therapeutics, including vaccines. MIT News says the team has filed a patent application and is pursuing commercialisation through BIZON Labs.
This is a laboratory and process-development report, not a clinical result. The announcement does not establish therapeutic efficacy, safety in people or a completed commercial manufacturing process. The original account also points to the ACS Nano paper linked below for the underlying work.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
Prefer to talk it through? Book a 30-minute discovery call